---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084860"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-07-20T11:12:37+00:00"
generated_at: "2026-07-20T11:15:16.512952+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Armata Pharmaceuticals promotes David House to CFO, effective July 17, 2026

## Summary
- David House appointed CFO; previously SVP Finance and principal financial officer since Aug 2024.
- Base salary $371,315; target bonus 50% of base; annual equity award target $300,000.
- Severance: 12 months base salary on involuntary termination without cause or for good reason.
- Change-in-control acceleration: full vesting of time-based equity if termination within 1 month before or 12 months after CIC.
- Also amended Pierre Kyme's employment agreement to conform change-in-control definition.

## SEC filing metadata
- accession: 0001104659-26-084860
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-07-20T11:12:37+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/0001104659-26-084860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926084860/tm2620782d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084860
- JSON: https://secwatch.observer/filing/0001104659-26-084860.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.